Recombinant Human ADA2, N-His

Introduction

Recombinant Human ADA2, also known as adenosine deaminase 2, is a protein that plays a crucial role in the immune system. It is a recombinant protein, meaning it is produced through genetic engineering techniques, and is used in various medical applications. In this article, we will discuss the structure, activity, and application of Recombinant Human ADA2.

Structure of Recombinant Human ADA2

Recombinant Human ADA2 is a 100-kDa protein that is composed of 932 amino acids. It is encoded by the CECR1 gene and is a member of the adenosine deaminase protein family. The protein consists of two domains, an N-terminal domain and a C-terminal domain, connected by a flexible linker region.

The N-terminal domain of Recombinant Human ADA2 contains the active site, which is responsible for the enzymatic activity of the protein. This domain also contains a zinc-binding motif, which is essential for the stability and function of the protein.

The C-terminal domain of Recombinant Human ADA2 is responsible for its interaction with other proteins and is involved in its role as a cytokine. This domain contains a fibronectin type III-like fold, which is involved in protein-protein interactions.

Activity of Recombinant Human ADA2

Recombinant Human ADA2 is an enzyme that catalyzes the conversion of adenosine to inosine. This activity is crucial for the regulation of adenosine levels, which play a role in various physiological processes, including inflammation and immune response.

In addition to its enzymatic activity, Recombinant Human ADA2 also acts as a cytokine, which is a signaling molecule involved in immune response and inflammation. It has been shown to promote the production of the anti-inflammatory cytokine interleukin-10, while inhibiting the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6.

Application of Recombinant Human ADA2

Recombinant Human ADA2 has been used in various medical applications due to its role in the immune system. One of its primary uses is in the treatment of patients with ADA2 deficiency, a rare genetic disorder that results in a deficiency of the ADA2 enzyme. This deficiency can lead to various symptoms, including immunodeficiency, vasculitis, and stroke. Recombinant Human ADA2 is used as a replacement therapy to restore the levels of ADA2 in these patients and improve their immune function.

In addition to its use in ADA2 deficiency, Recombinant Human ADA2 has also been investigated for its potential in treating other immune-related disorders, such as autoimmune diseases and chronic inflammatory conditions. It has been shown to have anti-inflammatory effects and has the potential to modulate the immune response in these conditions.

Recombinant Human ADA2 is also being studied for its potential as a biomarker for various diseases. Its levels have been found to be altered in patients with certain cancers, autoimmune diseases, and cardiovascular diseases. This makes it a potential candidate for diagnostic and prognostic purposes.

Conclusion

Recombinant Human ADA2 is a crucial protein in the immune system, with both enzymatic and cytokine activities. Its structure, activity, and application have been extensively studied, and it has shown promising results in the treatment of ADA2 deficiency and other immune-related disorders. Further research is needed to fully understand the potential of this protein in various medical applications.